News from regeneron pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 28, 2015, 01:00 ET

Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)  and Sanofi have entered into a new global collaboration to discover, develop and...

Jul 24, 2015, 15:17 ET

Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved...

Jul 24, 2015, 07:15 ET

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicine Agency's (EMA's) Committee for Medicinal...

Jul 08, 2015, 22:00 ET

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy...

Jul 08, 2015, 09:30 ET

Regeneron to Report Second Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2015

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2015 financial and operating...

Jun 30, 2015, 08:00 ET

New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol

Managing cholesterol is a private, emotional fight against a condition that cannot be seen or felt1. Now, a new film highlights individuals around...

Jun 29, 2015, 15:00 ET

Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Proceedings of the National Academy of Sciences (PNAS) has published a...

Jun 26, 2015, 03:00 ET

EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received...

Jun 25, 2015, 08:30 ET

Regeneron Announces 2015 Winners of the Regeneron Prize for Creative Innovation

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the third annual Regeneron Prize for...

Jun 09, 2015, 18:30 ET

FDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of...

Jun 09, 2015, 07:05 ET

Trading in Regeneron Common Stock Halted

 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that NASDAQ has halted trading of the company's common stock.  The...

May 21, 2015, 01:00 ET

Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6...

May 18, 2015, 12:30 ET

Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study...

May 07, 2015, 06:30 ET

Regeneron Reports First Quarter 2015 Financial and Operating Results

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2015 and provided an update on...

Apr 29, 2015, 09:30 ET

Regeneron Announces Upcoming 2015 Investor Conference Presentations

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: - Bank of...

Apr 10, 2015, 09:30 ET

Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2015 financial and operating results on...

Mar 25, 2015, 11:02 ET

EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME)

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA®...

Mar 15, 2015, 11:00 ET

Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that 18-month (78-week) results of a Phase 3 trial of Praluent™...

Mar 15, 2015, 11:00 ET
Sanofi logo

Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

 Sanofi and Regeneron Pharmaceuticals, Inc. today announced that 18-month (78-week) results of a Phase 3 trial of Praluent™ (alirocumab),...

Feb 26, 2015, 08:40 ET

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European...